

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – October 10, 2006

NOTICE OF STATUS CHANGE

This study will reopen to the accrual of 1 additional patient at dose level 0 effective Tuesday, October 10, 2006.

Please retain this notice with the protocol.